1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
685F1A4322D34DA9885258044005F5F04
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/85F1A4322D34DA9885258044005F5F04!OpenDocument
18
19OpenDocument
2054.91.4.56
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services New Product Development New Product Planning

Document Excerpt: Pharmaceutical New Product Planning Excellence: Resources and Showing Value

DB Image

ID: MD-536


Features:

18 Info Graphics

17 Data Graphics

125 Metrics

7 Narratives


Pages/Slides: 4


Published: 2016


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "Download Free Excerpt".


To return to the study abstract to purchase the full study - click here.

This excerpt includes research findings and metrics from document #5435 "Pharmaceutical New Product Planning Excellence: Resources and Showing Value"


Industries Profiled:
Biopharmaceutical; Pharmaceutical; Medical Device; Biotech; Health Care; Clinical Research; Laboratories; Manufacturing; Consumer Products; Diagnostic


Companies Profiled:
Alkermes; Zydus Cadila; GlaxoSmithKline ; Astellas; Roche; Novartis; Sanofi; Pfizer; Takeda Pharmaceuticals; Cytokinetics; Allergan; Medicago; Bayer; Galderma; Wockhardt


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.